Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Change in Accured Expenses (2024 - 2026)

Evommune (EVMN) reported Change in Accured Expenses of -$4.8 million for Q1 2026, down 128.97% year-over-year from $16.6 million in Q1 2025, and down 212.01% on a QoQ basis from $4.3 million in Q4 2025.

Evommune (EVMN) has 3 years of Change in Accured Expenses data on file, last reported at -$4.8 million in Q1 2026.

  • Quarterly Change in Accured Expenses fell 128.97% year-over-year to -$4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.8 million (changed N/A YoY) and the FY2025 annual result came in at $2.8 million, up 4.22% from the prior year.
  • Change in Accured Expenses eased to -$4.8 million in Q1 2026 per EVMN's latest filing, from $4.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.3 million in Q4 2025 and bottomed at -$4.8 million in Q1 2026.
  • The 3-year median for Change in Accured Expenses is -$1.1 million (2024), against an average of -$689500.0.
  • The widest annual swing landed in 2025, when Change in Accured Expenses surged 3169.29%; it then sank 128.97% in 2026.
  • Tracing EVMN's Change in Accured Expenses over 3 years: stood at -$140000.0 in 2024, then surged by 3169.29% to $4.3 million in 2025, then tumbled by 212.01% to -$4.8 million in 2026.
  • Per Business Quant, the three latest EVMN Change in Accured Expenses figures stand at -$4.8 million (Q1 2026), $4.3 million (Q4 2025), and -$2.1 million (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 931,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 70.50 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 107.70 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -176.03 Mn
10 Evommune 744.11 Mn 532.65 Mn - -4.81 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -4.81 Mn
Mar 31, 2026 -4.81 Mn
Dec 31, 2025 4.30 Mn
Dec 31, 2025 4.30 Mn
Mar 31, 2025 -2.10 Mn
Mar 31, 2025 -2.10 Mn
Dec 31, 2024 -140,000.00
Dec 31, 2024 -140,000.00